Tenenbaum A - Search Results

1

Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery.

Kogan A, Ram E, Levin S, Fisman EZ, Tenenbaum A, Raanani E, Sternik L. Kogan A, et al. Among authors: tenenbaum a. Cardiovasc Diabetol. 2018 Nov 29;17(1):151. doi: 10.1186/s12933-018-0796-7. Cardiovasc Diabetol. 2018. PMID: 30497472 Free PMC article.

2

Losartan and diabetic nephropathy: commentaries on the RENAAL study.

Fisman EZ, Tenenbaum A, Motro M. Fisman EZ, et al. Among authors: tenenbaum a. Cardiovasc Diabetol. 2002 Apr 8;1:2. doi: 10.1186/1475-2840-1-2. Cardiovasc Diabetol. 2002. PMID: 12119058 Free PMC article.

3

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR).

Tenenbaum A, Fisman EZ, Motro M. Tenenbaum A, et al. Cardiovasc Diabetol. 2003 Mar 23;2:4. doi: 10.1186/1475-2840-2-4. Cardiovasc Diabetol. 2003. PMID: 12834541 Free PMC article.

4

Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus.

Tenenbaum A, Fisman EZ, Schwammenthal E, Adler Y, Benderly M, Motro M, Shemesh J. Tenenbaum A, et al. Cardiovasc Diabetol. 2003 Nov 23;2:14. doi: 10.1186/1475-2840-2-14. Cardiovasc Diabetol. 2003. PMID: 14633284 Free PMC article.

5

Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up.

Fisman EZ, Motro M, Tenenbaum A, Leor J, Boyko V, Mandelzweig L, Sherer Y, Adler Y, Behar S. Fisman EZ, et al. Among authors: tenenbaum a. Eur J Cardiovasc Prev Rehabil. 2004 Apr;11(2):135-43. doi: 10.1097/01.hjr.0000124326.85096.ec. Eur J Cardiovasc Prev Rehabil. 2004. PMID: 15187817

6

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

Tenenbaum A, Motro M, Fisman EZ. Tenenbaum A, et al. Cardiovasc Diabetol. 2005 Sep 16;4:14. doi: 10.1186/1475-2840-4-14. Cardiovasc Diabetol. 2005. PMID: 16168052 Free PMC article. Review.

7

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.

Tenenbaum A, Fisman EZ, Motro M, Adler Y. Tenenbaum A, et al. Cardiovasc Diabetol. 2006 Sep 26;5:20. doi: 10.1186/1475-2840-5-20. Cardiovasc Diabetol. 2006. PMID: 17002798 Free PMC article. Review.

8

Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?

Tenenbaum A, Boyko V, Fisman EZ, Goldenberg I, Adler Y, Feinberg MS, Motro M, Tanne D, Shemesh J, Schwammenthal E, Behar S. Tenenbaum A, et al. Cardiovasc Diabetol. 2008 Jun 19;7:18. doi: 10.1186/1475-2840-7-18. Cardiovasc Diabetol. 2008. PMID: 18565233 Free PMC article.

9

A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

Fisman EZ, Tenenbaum A. Fisman EZ, et al. Among authors: tenenbaum a. Cardiovasc Diabetol. 2009 Jul 20;8:38. doi: 10.1186/1475-2840-8-38. Cardiovasc Diabetol. 2009. PMID: 19619327 Free PMC article. Review.

10

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ. Tenenbaum A, et al. Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24. Cardiovasc Diabetol. 2010. PMID: 20550659 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

323 results

Search Page

Filters